AbbVie Inc. (ABBV) AI Stock Summary
Profitable mega-cap trading near highs
Updated
Snapshot
AbbVie is a profitable mega-cap pharmaceutical company generating $61.16B in annual revenue, up 8.6% from the prior year. It maintains a very healthy 70.2% gross margin and produces massive free cash flow of $17.82B, significantly higher than its reported net income of $4.23B. The company carries substantial debt of $69.07B against $5.26B in cash, but its strong cash generation supports this leverage. The stock trades near its 52-week high after a recent acquisition announcement.
What's Happening Right Now
- Mon 29th Jun '26 · Clinical Trial: The company reported positive Phase 3 results for epcoritamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma, showing a 60% reduction in risk of disease progression or death.
- Mon 29th Jun '26 · Price Action: AbbVie stock hit a new 52-week high as the market digested the Apogee acquisition and the company's performance.
- Mon 29th Jun '26 · Regulatory: The European Medicines Agency's CHMP adopted a positive opinion for upadacitinib (RINVOQ) for the treatment of severe alopecia areata in adults and adolescents.
- Mon 22nd Jun '26 · Acquisition: AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $10.9 billion in cash to strengthen its immunology and inflammation portfolio.
Bottom Line
This is a cash-generating giant that has successfully navigated the patent cliff for Humira by growing revenue through new drugs like Skyrizi and Rinvoq. The $10.9B acquisition of Apogee Therapeutics signals a commitment to buying future growth in immunology rather than resting on current successes. Investors are paying up for this stability and pipeline expansion, as evidenced by the stock hitting a new 52-week high.